Antimicrobial resistance in Mycoplasma genitalium and Mycoplasma hominis: a systematic review in urology

Introduction: Mycoplasma genitalium and Mycoplasma hominis are urogenital mycoplasmas associated with urethritis, prostatitis, epididymitis, and pelvic inflammatory disease. In the last decade, acquired resistance to macrolides and fluoroquinolones in M. genitalium, together with intrinsic and acquired resistance to tetracyclines in M. hominis, have emerged as growing challenges in urology and sexual medicine.
Material and methods: A systematic review was conducted following the PRISMA guideline, searching PubMed, Scopus, and Web of Science (2015-2025). Clinical, epidemiological, and molecular studies describing genetic resistance mechanisms, as well as meta-analyses and clinical guidelines, were included. After applying inclusion and exclusion criteria, 42 articles were selected.
Results: In M. genitalium, macrolide resistance is associated with mutations in 23S rRNA (A2058G, A2059G), while fluoroquinolone resistance is linked to variants in parC and gyrA (S83I, D87N). In M. hominis, intrinsic macrolide resistance is complemented by the presence of tet(M), which contributes to doxycycline treatment failures. Globally, macrolide resistance in M. genitalium reaches 30-50% in Europe and the Americas, and over 60% in Asia; dual macrolide-fluoroquinolone resistance is emerging, with epidemic foci in Japan and China. In M. hominis, tetracycline resistance ranges from 10-30%, with regional variability.
Conclusions: Antimicrobial resistance in M. genitalium and M. hominis limits the effectiveness of traditional empirical therapies and requires the implementation of molecular detection and resistance testing. Resistance-guided treatment and epidemiological surveillance are essential to optimize clinical management and curb the spread of multidrug-resistant strains.

 

1. Pereyre S, Renaudin H, Charron A, et al. Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin. J Antimicrob Chemother 2006; 57:753-6. DOI: https://doi.org/10.1093/jac/dkl026

2. Jensen JS, Cusini M, Gomberg M, et al. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol 2022; 36:641-50. DOI: https://doi.org/10.1111/jdv.17972

3. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015; 61:418-26. DOI: https://doi.org/10.1093/cid/civ312

4. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18:757-89. DOI: https://doi.org/10.1128/CMR.18.4.757-789.2005

5. Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 2021;70:1-187. DOI: https://doi.org/10.15585/mmwr.rr7004a1

6. Qiu Y, Mao S, Li X, et al. Chinese advances in understanding and managing genitourinary tract infections caused by Mycoplasma genitalium, Mycoplasma hominis, and Ureaplasma urealyticum. Arch Microbiol 2024; 207:5. DOI: https://doi.org/10.1007/s00203-024-04204-z

7. Sandri A, et al. Antimicrobial resistance in Mycoplasma genitalium and clinical outcomes. Front Cell Infect Microbiol 2023;13:1163547. DOI: https://doi.org/10.3389/fcimb.2023.1155451

8. Chalker VJ, Sharratt MG, Rees CL, et al. Tetracycline resistance mediated by tet(M) has variable integrative conjugative element composition in Mycoplasma hominis strains isolated in the United Kingdom from 2005 to 2015. Antimicrob Agents Chemother 2021;65:e02513-20. DOI: https://doi.org/10.1128/AAC.02513-20

9. Pereyre S, et al. Emerging resistance in Mycoplasma hominis: clinical significance. J Antimicrob Chemother 2017; 72:1627-34.

10. Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:n71. DOI: https://doi.org/10.1136/bmj.n71

11. Piñeiro L, et al. Increases in macrolide resistance in Mycoplasma genitalium. Antibiotics (Basel) 2022; 11:923. DOI: https://doi.org/10.3390/antibiotics11111492

12. Katsuta T, et al. A2059G mutation conferring MLSB phenotype in Mycoplasma hominis. Antimicrob Agents Chemother 2018;62:e00025-18.

13. Braam JF, et al. Fluoroquinolone resistance-associated mutations in parC and gyrA of Mycoplasma genitalium. Pathogens 2022;11:538.

14. Hamasuna R, Le PT, Kutsuna S, et al. Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. PLoS One 2018; 13:e0198355. DOI: https://doi.org/10.1371/journal.pone.0198355

15. Meygret A, Le Roy C, Renaudin H, et al. Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. J Antimicrob Chemother 2018; 73:2696-703. DOI: https://doi.org/10.1093/jac/dky238

16. Manhart LE, Jensen JS, Bradshaw CS, et al. Efficacy of antimicrobial therapy for Mycoplasma genitalium infections. Clin Infect Dis 2015; 61:S802-17. DOI: https://doi.org/10.1093/cid/civ785

17. Ahmadi MH. Resistance to tetracyclines among clinical isolates of Mycoplasma hominis and Ureaplasma species: a systematic review and meta-analysis. J Antimicrob Chemother 2021; 76:865-75. DOI: https://doi.org/10.1093/jac/dkaa538

18. Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis 2020; 20:1302-14. DOI: https://doi.org/10.1016/S1473-3099(20)30154-7

19. Murray GL, Bradshaw CS, Bissessor M, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis 2017; 23:809-12. DOI: https://doi.org/10.3201/eid2305.161745

20. Le Roy C, Hénin N, Pereyre S, et al. Fluoroquinolone-resistant Mycoplasma genitalium, Southwestern France. Emerg Infect Dis 2016; 22:1677-9. DOI: https://doi.org/10.3201/eid2209.160446

21. Deguchi T, Ito S, Yasuda M, et al. Surveillance of the prevalence of macrolide and/or fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Japan. J Infect Chemother 2018;24:861-7. DOI: https://doi.org/10.1016/j.jiac.2018.08.009

22. Li L, Huang J, Zhang J, et al. Emerging multidrug resistance contributes to treatment failure in Mycoplasma genitalium-infected patients in China. Diagn Microbiol Infect Dis 2023; 105:115854. DOI: https://doi.org/10.1016/j.diagmicrobio.2022.115854

23. Mardassi BBA, Aissani N, Moalla I, et al. Evidence for the predominance of a single tet(M) gene sequence type in tetracyclineresistant clinical isolates of Ureaplasma parvum and Mycoplasma hominis from Tunisia. J Med Microbiol 2012; 61:1080-6. DOI: https://doi.org/10.1099/jmm.0.044016-0

24. Abavisani M, Keikha M. Global analysis on the mutations associated with multidrug-resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2023; 22:70. DOI: https://doi.org/10.1186/s12941-023-00627-6

25. Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020; 71:1461-8. DOI: https://doi.org/10.1093/cid/ciz1031

26. Trinchieri A, Abdelrahman KM, Bhatti KH, et al. Spectrum of causative pathogens and resistance rates to antibacterial agents in bacterial prostatitis. Diagnostics (Basel) 2021; 11:1333. DOI: https://doi.org/10.3390/diagnostics11081333

27. Hini´c V, Mouttet F, Wüthrich D, et al. Unexpected Mycoplasma hominis infection in two renal transplant recipients, discovered accidentally in the bacterial workup. Transpl Infect Dis 2021; 23:e13481.

28. Ahmadi MH, Mirsalehian A, Sadighi Gilani MA, et al. Asymptomatic infection with Mycoplasma hominis negatively affects semen parameters and leads to male infertility as confirmed by improved semen parameters after antibiotic treatment. Urology 2017;100:97-102. DOI: https://doi.org/10.1016/j.urology.2016.11.018

29. Horner PJ, Donders G, Cusini M, et al. Should we be testing for urogenital Mycoplasma genitalium? Evidence-based review and recommendations. Clin Microbiol Infect 2018; 24:521-9.

30. Waites KB, Crabb DM, Duffy LB, et al. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational antimicrobial, AZD0914, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 2016; 60:1919-24. DOI: https://doi.org/10.1128/AAC.01734-16

31. Clarke EJ, Cherny KE, Fairley CK, et al. Efficacy of minocycline for the treatment of Mycoplasma genitalium. Open Forum Infect Dis 2023; 10:ofad427. DOI: https://doi.org/10.1093/ofid/ofad427

32. Jensen JS, Hansen HT, Unemo M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against Mycoplasma genitalium strains, including macrolide-resistant and multidrugresistant ones. Antimicrob Agents Chemother 2014; 58:6113-8. DOI: https://doi.org/10.1128/AAC.02411-14

33. World Health Organization. WHO expands guidance on sexually transmitted infections and reviews country progress on policy implementation. Available from: https://www.who.int/news/item/26-07-2025-who-expands-guidance-on-sexually-transmitted-infections-andreviews-country-progress-on-policy-implementation

34. Ke W, Li D, Tso LS, et al. Macrolide and fluoroquinolone associated mutations in Mycoplasma genitalium in a retrospective study of male and female patients seeking care at a STI clinic in Guangzhou, China, 2016-2018. BMC Infect Dis 2020; 20:950. DOI: https://doi.org/10.1186/s12879-020-05659-3

35. Chua TP, Vodstrcil LA, Murray GL, et al. Evolving patterns of macrolide and fluoroquinolone resistance in Mycoplasma genitalium: an updated systematic review and meta-analysis. Lancet Microbe 2025; 6:101047. DOI: https://doi.org/10.1016/j.lanmic.2024.101047

36. UK Health Security Agency. Mycoplasma genitalium antimicrobial resistance surveillance (MARS) report: 2023. UKHSA; 2024. Available from: https://www.gov.uk/government/publications/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars/mycoplasma-genitalium-antimicrobial-resistancemars-report-2023

37. Muller EE, Mahlangu MP, Lewis DA, et al. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014. BMC Infect Dis 2019; 19:148. DOI: https://doi.org/10.1186/s12879-019-3797-6

38. Melendez JH, Hardick J, Onzia A, et al. Retrospective analysis of Ugandan men with urethritis reveals Mycoplasma genitalium and associated macrolide resistance. Microbiol Spectr 2022; 10:e0230421. DOI: https://doi.org/10.1128/spectrum.02304-21

39. Song J, Wu X, Kong Y, et al. Prevalence and antibiotic resistance of Ureaplasma species and Mycoplasma hominis in Hangzhou, China, from 2013 to 2019. Front Microbiol 2022; 13:982429. DOI: https://doi.org/10.3389/fmicb.2022.982429

40. Ramaloko WT, Maningi NE, Osei Sekyere J. Global prevalence, resistance rates, and underlying resistance mechanisms of clinical Mycoplasma and Ureaplasma species. J Appl Microbiol 2025;136:lxae308. DOI: https://doi.org/10.1093/jambio/lxae308

41. Boujemaa S, Mlik B, Mardassi H, et al. Clonal spread of tetracycline resistance among Mycoplasma hominis clinical strains, Tunisia. Infect Drug Resist 2020;13:2093-7. DOI: https://doi.org/10.2147/IDR.S249630

42. Wen X, Nobakht MS, Yang Y, et al. Tetracyclines resistance in Mycoplasma and Ureaplasma urogenital isolates derived from humans: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2023; 22:83. DOI: https://doi.org/10.1186/s12941-023-00628-5